Apoptosis is an inducible response to developmental or environmental stimuli that culminates in cell suicide. While cell death is essential for development and homeostasis, increased apoptosis leads to embryonic lethality and degenerative disorders. In contrast, increased survival is conducive to autoimmune diseases and cancer. The pro-inflammatory cytokine tumor necrosis factor alpha (TNFa) is produced in immune and inflammatory responses and triggers competing signaling pathways that determine whether a cell lives or dies. One pathway promotes cell death, the other leads to activation of the Rel/NF-kB transcription factors and the inhibition of apoptosis. Experimental evidence indicates that Rel/NF-kB regulates the expression of genes that confer resistance to death-inducing signals. The important role of Rel/NF-kB in immune and inflammatory responses and in leukemia/lymphomagenesis led one to search for the anti-apoptotic genes that it controls. Dr. Gelinas has recently identified Bfl-1/A1 as a direct transcriptional target of NF-kB. Bfl-1/A1 is a pro-survival factor in the Bcl-2-family of apoptosis regulators. Bfl-1 gene expression was dependent on NF-kB activity and suppressed TNFa-induced under conditions where endogenous NF-kB activity was inhibited. Bfl-1 promoter analysis revealed a consensus kB DNA site responsible for its Rel/NF-kB-dependent induction. These findings are consistent with reports of bfl-1/a1 gene induction by pro-inflammatory cytokines in endothelial, leukemic and hemopoietic cells, and of its ability to confer resistance to various death-inducing agents. The preferential expression of Bfl-1 in hematopoietic cells and tissues suggests that it may be critical for carrying-out the protective role of Rel/NF-kB in the immune system and during inflammation. The ability of Bfl-1 to cooperate with Adenovirus E1A to transform cells and its overexpression in certain cancers also suggest that Bfl-1 activation may be an important means by which NF-kB functions in oncogenesis and promotes cell resistance to anti-cancer therapy. This proposal is an extension of these preliminary studies. Dr. Gelinas will characterize the anti-apoptotic and oncogenic functions of Bfl-1 and establish its contribution to the Rel/NF-kB survival pathway. Experiments will define the mechanism by which Bfl-1 blocks the apoptotic cascade in lymphoid cells (Aim 1), evaluate its contribution to Rel/NF-kB-mediated cell survival (Aim 2), and assess its role in malignancy (Aim 3). These studies will help to decipher the mechanisms that antagonize the cellular apoptotic response and will provide important information to understand their contribution to oncogenesis and to the resistance of tumor cells to anti-cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA083937-01A1
Application #
6192911
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mufson, R Allan
Project Start
2000-07-01
Project End
2005-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
1
Fiscal Year
2000
Total Cost
$264,545
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Biochemistry
Type
Schools of Medicine
DUNS #
622146454
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Fan, Gaofeng; Simmons, Matthew J; Ge, Sheng et al. (2010) Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood 115:3559-69
Simmons, M J; Fan, G; Zong, W-X et al. (2008) Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist. Oncogene 27:1421-8
Fan, Yongjun; Dutta, Jui; Gupta, Nupur et al. (2008) Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615:223-50
Pegman, Pamela M; Smith, Sinead M; D'Souza, Brendan N et al. (2006) Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. J Virol 80:8133-44
Dutta, J; Fan, Y; Gupta, N et al. (2006) Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25:6800-16
Kucharczak, J F; Simmons, M J; Duckett, C S et al. (2005) Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. Cell Death Differ 12:1225-39
D'Souza, Brendan N; Edelstein, Leonard C; Pegman, Pamela M et al. (2004) Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol 78:1800-16
Rayet, Beatrice; Fan, Yongjun; Gelinas, Celine (2003) Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity. Mol Cell Biol 23:1520-33
Kucharczak, Jerome; Simmons, Matthew J; Fan, Yongjun et al. (2003) To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22:8961-82